AXSM Axsome Therapeutics, Inc.
AXSM Axsome Therapeutics, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $183.30 · VWAP $194.13 · -19.1% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
AXSM Price Structure
Loading timeframes…
Peers
Every watchlist AXSM belongs to, members best 30-day change first — AXSM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Axsome Therapeutics furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. Its 10-Q reports (GAAP): revenue $218M, diluted EPS -$0.99, net income -$51M.
full note →Against street estimates
How AXSM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about AXSM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 3 days ago · Oct 14
- Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
- Axsome Therapeutics to Report Second Quarter 2026 Financial
- Axsome Therapeutics Reports Fourth Quarter and ... - BioSpace
- Axsome Therapeutics, Inc. (AXSM) 8-K Earnings Release - Feb 2026
- Axsome Therapeutics Inc (AXSM) Live Share Price, Invest From India
AXSM research tape
53 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.